Kendra Wulczyn is a Nephrology physician. OpenAlex indexes 25 publications with 1,058 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
165 Cambridge St Ste 302
Boston, MA 021142752
Telephone
617-726-5050Provider last certified this registry record 19 Sept 2022.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
64.4%ACE inhibitor31.1%Lisinopril100%Part D<11 patientsLoop diuretic17.8%Torsemide100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
35.6%SGLT2 inhibitor35.6%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Patient-Reported Outcome Measure (PROM) Utilization to Advance Patient Centered CKD Care
Massachusetts General Hospital
FY2026$197,474K23DK140642 - Patient-Reported Outcome Measure (PROM) Utilization to Advance Patient Centered CKD Care
Massachusetts General Hospital
FY2025$199,130K23DK140642 - Determinants of Uremic Symptoms in CKD and Associations to Clinical Outcomes
Massachusetts General Hospital
FY2023$47,402F32DK131793
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effect of Parathyroidectomy on Albuminuria: Presurgical and Postsurgical Analysis
Journal of the American Society of Nephrology
2025 - Development and Validation of a Mortality Risk Prediction Model for Patients with Prevalent ESKD on Hemodialysis
Journal of the American Society of Nephrology
2025 - Predicting Significant Symptom Burden Following Dialysis Initiation: Two-Year Risk Model
Journal of the American Society of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”